| Position | Action |
|---|---|
| Current core position | MAINTAIN - do not chase into $436 resistance given six failed attempts and deteriorating momentum |
| Any rally into $430-450 zone | TRIM 15-25% to lock gains and reduce concentration ahead of Q2 2026 earnings |
| Ahead of Q2 2026 earnings | WAIT - do not commit fresh capital as expectations are elevated, creating asymmetric downside on a miss |
| (a) Confirmed close above $436 with volume >5M shares, OR (b) flush to $390-400 with capitulation volume | ADD on either trigger for better risk/reward |
| Close below $400 on volume | STOP-LOSS - invalidates bullish structural thesis and warrants further trimming |
| After Q2 2026 earnings (mid-to-late July 2026) | RE-EVALUATE - upgrade to Overweight on clean beat with raised guide; downgrade to Underweight on miss or soft guide |
UNH is in a mid-cycle earnings recovery with a vertically integrated Optum platform moat that makes the current forward P/E of 18.5x a generational entry point, not expensive as bears claim.
| Indicator | Value | Signal |
|---|---|---|
| Close | $415.36 | — |
| 10 EMA | $420.66 | bearish |
| 50 SMA | $410.09 | neutral |
| 200 SMA | $341.79 | bullish |
| Bollinger Middle | $424.20 | — |
| Bollinger Upper Band | $435.55 | — |
| Bollinger Lower Band | $412.86 | — |
| RSI | 47.73 | neutral |
| MACD | +2.05 | bearish |
| MACD Signal | +4.52 | — |
| MACD Histogram | -2.48 | bearish |
| ATR | $11.73 | — |
| Close vs 200 SMA | $415 vs $342 (+21.5%) | bullish |
| Close vs 50 SMA | $415 vs $410 (+1.3%) | neutral |
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
HOLD UNH: Maintain core position with no new capital deployment, trim 15-25% into resistance, add on breakout or flush
HOLD is mechanically consistent because the aggressive Buy/Overweight case requires multiple simultaneous favorable outcomes (MLR normalization, MA repricing success, IDR non-recurrence, technical breakout confirmation, regulatory benignity) while the bear only needs one to disappoint. With UNH sitting 21% above the rising 200 SMA ($342), institutional accumulation signals from Janus Henderson and Vulcan Value Partners, and the Optum moat intact, quality premium historically dominates near-term multiple risk. The neutral analyst's framework—trim into strength, wait for Q2 print, stage adds at breakout or flush—is the most operationally specific and risk-aware approach. The prior UNH Overweight (2026-07-31) produced +0.2% absolute but -1.2% alpha for exactly the reasons this setup presents: MACD rolling over with live regulatory overhangs warrants HOLD with defined stops rather than treating momentum deterioration as secondary to fundamental recovery.
When: Confirmed close above $436 with volume >5M shares
Then: ADD - signals institutional conviction and invalidates the $436 ceiling
↩ rebuts: “Bear argument that this is temporary or unsustainable”
UNH at $415 is a dangerous trap disguised as a generational entry, with $130B of goodwill/intangibles on a structurally fragile balance sheet, consensus-forward EPS of $22.44 that requires perfection across seven independent variables while the bear needs just one to break — making this a distribution opportunity where the path of least resistance is sideways to down until the cycle proves durable.
· concedes: Long-term uptrend is intact (200 SMA rising, price above); Q1 2026 EPS of $6.90 did print above expectations; $22.8B FCF is a positive; Janus Henderson and Vulcan Value Partners are quality institutional investors with skin in the game; Original technical report concluded HOLD with uptrend intact — not outright bearish; $22.44 consensus EPS estimate exists and provides a floor if achievable; Q4 2025 trough was genuinely bad and may have been the cycle low; Optum Health growth is real even if uncertain in timing/magnitude
→ vs conservative: Leaning on six failed attempts at $436, MACD bearish cross at +2.05, and 10 EMA rollover are textbook lag indicators that scream BUY in a stock that rallied from sub-$260 to $436 in four months—the supply is being absorbed, creating a coil, not terminating a trend
→ vs conservative: Operating margin compression from 8.7% to 4.2% is a structural misread; Q1 2026 showed $8.99 billion operating income and $6.90 EPS, a 23x sequential recovery, making the 4.2% number stale data the market has already digested
→ vs conservative: The asymmetric math is being completely missed—sell-side fair value of $475.23 represents 15% upside at current $415 price, not a balanced risk-reward as described
→ vs neutral: Waiting for breakout confirmation is the most expensive mistake in trend-following—by the time UNH proves itself above $436 with volume, you are buying at $445 chasing, missing the disciplined entry
→ vs neutral: The stop at $400 is inconsistent with current price action—the 50 SMA at $408-$410 is the only relevant structural level, not an arbitrary number
→ vs conservative: Q2 earnings are not binary—they are probability-weighted, and the base case is continued execution; the bear needs multiple things to go wrong simultaneously
| Close vs 10 EMA | $415 vs $421 | bearish |
Support: 412 · 413 · 410 · 395 | Resistance: 424 · 425 · 436
UNH exhibits a mixed technical picture: the long-term uptrend remains intact with price 21.5% above the 200 SMA at $341.79, but short-term momentum has turned bearish with MACD below its signal line (histogram at -2.48) and price trading below the 10 EMA at $420.66. The stock is consolidating in a $412-$436 range after six failed attempts to break above $436 resistance, with RSI reset to a neutral 47.73 from overbought extremes of 85+ in mid-May. The 50 SMA at $410.09 and lower Bollinger Band at $412.86 represent critical support zones; a breakdown below $410 would damage the medium-term uptrend, while a break above $436 would signal continuation toward $450+. ATR has risen to $11.73, indicating elevated volatility requiring appropriate position sizing and stops of ~$18-23 (1.5x-2x ATR). The actionable recommendation is HOLD—maintain existing positions with stops near $410, but await a decisive break of the $410-$436 range before committing fresh capital.
Market Cap
$377.2B
P/E (TTM)
31.32x
Forward P/E
18.51x
PEG Ratio
1.28
Price/Book
3.60x
EPS (TTM)
$13.26
Forward EPS
$22.44
Dividend Yield
2.24%
Beta
0.632
52-Week High
$461.62
52-Week Low
$236.95
50-Day MA
$410.16
200-Day MA
$344.69
Revenue (TTM)
$450.1B
Revenue 2025
$447.6B
Revenue Growth 2025
+11.8%
Gross Profit 2025
$82.9B
Operating Income 2025
$19.0B
Operating Margin 2025
4.2%
EBITDA 2025
$23.1B
Net Income 2025
$12.1B
Diluted EPS 2025
$13.23
Interest Expense 2025
$4.00B
Total Assets (Q1 2026)
$312.6B
Total Liabilities (Q1 2026)
$207.3B
Stockholders' Equity (Q1 2026)
$97.9B
Total Debt (Q1 2026)
$77.9B
Long-Term Debt (Q1 2026)
$71.4B
Cash & Equivalents (Q1 2026)
$28.0B
Net Debt (Q1 2026)
$49.9B
Goodwill (Q1 2026)
$110.5B
Intangible Assets (Q1 2026)
$20.1B
Current Ratio
0.78
Debt/Equity
69.2%
Operating Cash Flow 2025
$19.7B
Capital Expenditures 2025
($3.6B)
Free Cash Flow 2025
$16.1B
FCF (TTM)
$22.8B
Acquisitions 2025
($4.5B)
Dividends Paid 2025
($7.9B)
Buybacks 2025
($5.5B)
Diluted Shares Outstanding
~910M
Annual Dividend
~$8.80/share
Profit Margin
3.14%
Operating Margin
7.13%
Return on Equity (ROE)
14.15%
Return on Assets (ROA)
4.38%
EPS (Q1 2026)
$6.90
Strengths
Concerns
UnitedHealth Group is a diversified healthcare conglomerate operating UnitedHealthcare (insurance) and Optum (health services) segments, generating $450.1B in TTM revenue. The company experienced a significant 2025 earnings trough ($13.23 EPS vs. $23.86 peak in 2023) due to elevated medical loss ratios and Change Healthcare cyberattack costs, but Q1 2026 shows strong recovery ($6.90 EPS, highest in the past year) with consensus expecting 70% earnings growth to $22.44 EPS in 2026. The balance sheet remains strong with $22.8B TTM free cash flow, manageable net debt of $49.9B, and a secure 2.24% dividend yielding 14% FCF coverage. The forward P/E of 18.51x is attractive given the earnings inflection, but medical cost inflation, $110.5B goodwill, and regulatory scrutiny remain key risks to the investment thesis.